e-learning
resources
Barcelona 2010
Wednesday, 22.09.2010
New mechanisms in chronic lung diseases
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
The VIP gene is a dominant modulator of the pulmonary circulation
S. Said, S. Hamidi (Northport, United States Of America)
Source:
Annual Congress 2010 - New mechanisms in chronic lung diseases
Session:
New mechanisms in chronic lung diseases
Session type:
Oral Presentation
Number:
5545
Disease area:
Pulmonary vascular diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
S. Said, S. Hamidi (Northport, United States Of America). The VIP gene is a dominant modulator of the pulmonary circulation. Eur Respir J 2010; 36: Suppl. 54, 5545
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
The definition of pulmonary hypertension: history, practical implications and current controversies
Asbestosis
Related content which might interest you:
Is TGFb a central mediator in the development of pulmonary fibrosis?
Source: Research Seminar 2010 - Novel insights in pulmonary fibrogenesis: from bench to bedside Research Seminar
Year: 2010
Microarray analysis of pulmonary gene expression in mice lacking the vasoactive intestinal peptide (VIP) gene: confirmation of a role in asthma and pulmonary arterial hypertension (PAH)
Source: Annual Congress 2006 - Cellular mechanisms of airway disease
Year: 2006
Gene expression alterations in mice lacking the VIP gene are conducive to pulmonary arterial hypertension and pulmonary vascular remodeling
Source: Annual Congress 2007 - Cellular and molecular aspects of pulmonary hypertension
Year: 2007
Macitentan modulates pulmonary mRNA levels of gremlin 1 in a rat model of pulmonary arterial hypertension
Source: International Congress 2019 – Pulmonary hypertension with lung diseases and experimental pulmonary hypertension
Year: 2019
Classical transient receptor potential channel 6 (TRPC6) is a key regulator of acute hypoxic pulmonary vasoconstriction
Source: Eur Respir J 2007; 30: Suppl. 51, 55s
Year: 2007
Interleukin-13-dependent regulation of endothelin-1 expression in pulmonary arterial hypertension
Source: Annual Congress 2007 - Pulmonary hypertension
Year: 2007
Expression vasoactive intestinal peptide and related receptors in overcirculation-induced pulmonary hypertension in piglets
Source: Eur Respir J 2006; 28: Suppl. 50, 659s
Year: 2006
Pulmonary arterial hypertension (PAH) in mice lacking the vasoactive intestinal polypeptide (VIP) gene: morphometric evidence for vascular remodeling
Source: Annual Congress 2006 - Signalisation in the pulmonary vasculature: new pathways and wrong signals
Year: 2006
Inhibition of microRNA-17 improves lung and heart function in experimental pulmonary hypertension
Source: Annual Congress 2011 - Treatments for pulmonary hypertension in human and experimental models
Year: 2011
Optimization of tissue targeting properties of macitentan, a new dual endothelin receptor antagonist, improves its efficacy in a rat model of pulmonary fibrosis associated with pulmonary arterial hypertension
Source: Annual Congress 2011 - Treatment of human pulmonary hypertension
Year: 2011
The pathophysiological role of novel pulmonary arterial hypertension gene
SOX17
Source: Eur Respir J, 58 (3) 2004172; 10.1183/13993003.04172-2020
Year: 2021
Enhancement of pulmonary vascular remodelling and inflammatory genes with VIP gene deletion
Source: Eur Respir J 2008; 31: 135-139
Year: 2008
Expression and role of the nerve growth factor NGF in pulmonary hypertension
Source: Annual Congress 2011 - Pathobiology of experimental pulmonary hypertension
Year: 2011
Expression of the serotonin 1b receptor in experimental pulmonary hypertension
Source: Eur Respir J 2003; 22: 408-412
Year: 2003
Endothelin receptor expression in idiopathic pulmonary arterial hypertension: effect of bosentan and epoprostenol treatment
Source: Eur Respir J 2011; 38: 851-860
Year: 2011
Effect of medroxyprogesterone on arterial blood gases, leptin and neuropeptide Y in postmenopausal females
Source: Eur Respir J 2002; 20: 1413-1418
Year: 2002
NGF induces pulmonary arterial hyperreactivity through connexin 43 increased expression
Source: Virtual Congress 2020 – Pathophysiology of pulmonary hypertension
Year: 2020
Late Breaking Abstract - NGF induces pulmonary arterial hyperreactivity through increased connexin-43 expression: potential role in pulmonary hypertension
Source: International Congress 2018 – Molecular mechanisms and treatment of pulmonary hypertension
Year: 2018
Dependence of mean pulmonary artery pressure from cytokine inflammation activity and remodeling index of pulmonary circulation
Source: Eur Respir J 2006; 28: Suppl. 50, 657s
Year: 2006
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept